Flemming Pociot

ORCID: 0000-0003-3274-5448
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes and associated disorders
  • Pancreatic function and diabetes
  • Diabetes Management and Research
  • Immune Cell Function and Interaction
  • MicroRNA in disease regulation
  • T-cell and B-cell Immunology
  • Diet, Metabolism, and Disease
  • Metabolism, Diabetes, and Cancer
  • Cancer-related molecular mechanisms research
  • Endoplasmic Reticulum Stress and Disease
  • RNA modifications and cancer
  • Diabetes Treatment and Management
  • Genetic Associations and Epidemiology
  • Immunodeficiency and Autoimmune Disorders
  • Immune Response and Inflammation
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diet and metabolism studies
  • Glycosylation and Glycoproteins Research
  • Extracellular vesicles in disease
  • Genetics and Neurodevelopmental Disorders
  • Celiac Disease Research and Management
  • Metabolomics and Mass Spectrometry Studies
  • Atherosclerosis and Cardiovascular Diseases
  • Adipose Tissue and Metabolism
  • Circular RNAs in diseases

Steno Diabetes Centers
2015-2025

University of Copenhagen
2016-2025

Herlev Hospital
2015-2025

Capital Region of Denmark
2018-2023

Copenhagen University Hospital
2013-2022

University of Tennessee Health Science Center
2022

University of Cambridge
2022

Gentofte Hospital
2015-2021

Glostrup Hospital
2010-2014

Lund University
2005-2013

Abstract. In the present study we searched for restriction fragment length polymorphisms (RFLP) in human interleukin‐1β (IL‐lβ) gene and correlations to monocyte (Mo) function non‐related healthy donors insulin‐dependent diabetic patients. We demonstrated a diallelic polymorphism with enzyme TaqI consisting of fragments 9.4 kb 13.4 kb. No differences allele or genotype frequencies this RFLP were observed between randomly selected controls patients diabetes mel‐litus (IDDM). However, when...

10.1111/j.1365-2362.1992.tb01480.x article EN European Journal of Clinical Investigation 1992-06-01

The tumor necrosis factor (TNF) alpha gene lies within the class III region of major histocompatibility complex (MHC), telomeric to II and centromeric I region. We have recently described first polymorphism human TNF-alpha locus. This is biallelic promoter Frequency analysis polymorphism, using polymerase chain reaction single-stranded conformational in HLA-typed individuals, reveals a very strong association between uncommon TNF allele HLA A1, B8, DR3 alleles. other MHC alleles raises...

10.1084/jem.177.2.557 article EN The Journal of Experimental Medicine 1993-02-01

We have investigated the correlation between different tumor necrosis factor (TNF) and class II major histocompatibility complex alleles in lipopolysaccharide- or phytohemagglutinin-induced secretion of TNF-alpha TNF-beta by human monocytes peripheral blood mononuclear cells 87 unrelated Danish male individuals. Significant differences secretory capacity TNF NcoI restriction fragment length polymorphisms, TNFa TNFc microsatellite DR were identified. No with was found for any markers studied....

10.1002/eji.1830230135 article EN European Journal of Immunology 1993-01-01

This study aims to identify key miRNAs in circulation, which predict ongoing beta-cell destruction and regeneration children with newly diagnosed Type 1 Diabetes (T1D). We compared expression level of sera from new onset T1D age-matched healthy controls related the levels function glycaemic control. Global miRNA sequencing analyses were performed on pools two cohorts ( n = 275 129, resp.) one control group 151). identified twelve upregulated human patients (miR-152, miR-30a-5p, miR-181a,...

10.1155/2012/896362 article EN cc-by Experimental Diabetes Research 2012-01-01

Type 1 diabetes is a common, multifactorial disease with strong familial clustering (genetic risk ratio [λS] ∼ 15). Approximately 40% of the aggregation type can be attributed to allelic variation HLA loci in major histocompatibility complex on chromosome 6p21 (locus-specific λS 3). Three other susceptibility have been clearly demonstrated based their direct effect risk, INS (chromosome 11p15, odds [OR] 1.9), CTLA4 2q33, OR 1.2), and PTPN22 1p13, 1.7). However, large proportion remains...

10.2337/diabetes.54.10.2995 article EN Diabetes 2005-10-01
Coming Soon ...